/
We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that was launched in February 2026 (the Lon…
The business is unprofitable at the operating level (-162.87% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 16.7% YoY with margins expanding 161.1pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$2M
▲ +16.7% YoY
Net Income (TTM)
-$4M
▲ +32.7% YoY
Op. Margin
-162.87%
▲ +161.1pp YoY
ROIC
-145.02%
▲ +46.2pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$2M
▲ +26.1% YoY
Net Debt
$258K
Cash & Equiv.
$1M
Continue Research